Kornimate/medical-research-clean huggingface dataset:
the preventive value of acupoint sensitization based on stable angina pectoris

Conditions: The Clinical Value of Acupoint Sensitization

Summary: this study, taking stable angina pectoris as a research carrier, aims to explore the preventive value of acupoint sensitization by conducting a double-blind multi-center randomized controlled trial to compare the effect of stimulating acupoints with different sensitivity on the prevention of angina pectoris. after the inclusion of eligible patients, the pressure-pain threshold of disease-related acupoints will be detected by using von frey detector. then, the patients will be randomly divided into experimental group and control group. the patients in experimental group will be given acupoints pressure on the five acupoints with the lowest pressure-pain threshold, while the patients in control group will be given acupoints pressure on the five acupoints with the five acupoints with the highest pressure-pain threshold. the two groups will be treated with acupoints pressure 12 times within 4 weeks. the patients will be evaluated three times at baseline, the end of treatment and four weeks after the end of treatment respectively, including angina attack frequency, ccs classification and saq score.


Eligibility criteria:
inclusion criteria: * patients with stable angina pectoris and symptoms of chest pain * the duration of onset was more than 3 months, and the number of angina attacks in the past month was not less than 2 * not younger than 35 years old and not older than 80 years old * patients will participate in the study voluntarily and have signed the informed consent exclusion criteria: * patients with mental retardation * patients were contraindicated or unable to complete acupoint sensitization test * patients with cardiovascular, digestive, urinary, respiratory, blood, nervous, endocrine system and other serious primary diseases * patients with bleeding, allergy constitution * patients with abnormal skin or peripheral nerve sensation, abnormal pain sensation, skin ulceration at the sensitization detection site * patients with unsatisfactory clinical treatment of hypertension and diabetes
neurally adjusted ventilatory assist for neonates with congenital diaphragmatic hernias

Conditions: Congenital Diaphragmatic Hernia

Summary: congenital diaphragmatic hernias (cdh) are typically repaired surgically in the first few days of a neonate's life. following surgical repair, infants usually require ventilatory support to ensure adequate oxygenation. traditionally assist control ventilation (acv) has been used to support neonates with cdh. due to delivering a fixed pressure of oxygen, acv has been associated with barotrauma and long-term lung damage. a more recent approach to ventilation is non-invasive neurally adjusted ventilatory assist (niv-nava). niv-nava uses electrical signals of the diaphragm to deliver a proportional pressure of oxygen. our dual-centre randomised cross-over trial aims to investigate the efficacy of niv-nava compared to acv for supporting neonates with cdh.

background: congenital diaphragmatic hernias (cdh) are typically repaired surgically in the first few days of a neonate's life. following surgical repair, infants usually require ventilatory support to ensure adequate oxygenation. traditionally assist control ventilation (acv) has been used to support neonates with cdh. due to delivering a fixed pressure of oxygen, acv has been associated with barotrauma and long-term lung damage. a more recent approach to ventilation is non-invasive neurally adjusted ventilatory assist (niv-nava). niv-nava uses electrical signals of the diaphragm to deliver a proportional pressure of oxygen. evidence suggests that nava may reduce physiological parameters associated with lung pressure and hence reduce the risk of iatrogenic lung injury. aims: our aim is to compare the oxygenation index (oi) of neonates with cdh, ventilated with acv and niv-nava. the oi is calculated as the fractured of inspired oxygen x mean airway pressure x partial pressure of oxygen/100. the oxygenation index is used as a marker of hypoxic respiratory failure in infants with cdh and forms the basis of the criteria to administer nitric oxide. methods: our investigation is a dual-centre randomised cross-over trial. infants will be identified and parents counselled in the first few days following delivery. neonates that meet inclusion criteria will be randomised to receive either niv-nava or acv first, followed by the other method of ventilation. infants will be stabilised on acv one-hour prior to entering the trial. on entry into the trial, they will receive 4-hours of each ventilatory method with a 20-minute stabilisation break in between.

Eligibility criteria:
inclusion criteria: * infants born with congenital diaphragmatic hernia more than 34-weeks gestation exclusion criteria: * receiving nitric oxide * requiring an fio2 more than 80% to maintain spo2: 85-95%. * severe chromosomal abnormality * severe cardiac anomalies requiring corrective surgery * renal anomalies * skeletal deformities suspected to impede thoracic or lung development * severe central nervous system anomalies suspected to impede diaphragmatic signalling * use of neuromuscular blocking agents * contraindication to nasogastric tube insertion
physical disability in patients treated with betaferon

Conditions: Multiple Sclerosis

Summary: to gather observation data about physical disability progression, safety and adherence during the use of betaferon in daily practice. patients with any type of multiple sclerosis (ms) (mrrs) (psms), under treatment with betaferon.open multicentric observational study.24 months.evaluation of physical disability in patients treated with betaferon, using kurtzke's expanded disability scale (edss) in biannual periods


Eligibility criteria:
inclusion criteria: * patients with a first demyelinating event suggestive of ms, as well as patients with remittent recurrent ms (rrms), secondary progressive ms (spms) and primary progressive ms (ppms) will be able to join the study. exclusion criteria: * pregnancy * patients with a history of hypersensitivity to natural or recombinant interferon-beta, human albumin or to any of the excipients * patients with a history of severe depressive disorders and/or suicidal ideation * patient with decompensated liver disease * patient with epilepsy not adequately controlled by treatment

Keywords: ms multiple sclerosis betaferon colombia
a study of wx390 in patients with advanced solid tumors

Conditions: Solid Tumor

Summary: the goal of this clinical trial is to evaluate the efficacy and safety of wx390 in patients with advanced solid tumors. the main questions it aims to answer are: * pfs, os, dor at week 48; * antitumor effects at week 24 and week 48. participants will be treated with wx390 orally, and follow the efficacy and safety evaluation according to the protocol.

this study will be an open-label, multicenter phase ii clinical trial. after being informed about the study and potential risks, all patients giving written informed consent will undergo a 4-week screening period to determine eligibility for study entry. and then patents will be administered for 12 cycles treatment and 30 days safety follow up after the last dose of treatment. the efficacy and safety measures will be conducted and collected every cycle.

Eligibility criteria:
inclusion criteria: * ≥18 years of age * histological or cytological confirmed advanced solid tumor, standard regimen failed * eastern cooperative oncology group (ecog) performance status of 0-1 * life expectancy of more than 3 months * at least one measurable lesion according to recist 1.1 * adequate organ function * signed and dated informed consent exclusion criteria: * anti-cancer therapy within 30 days prior to the initiation of investigational treatment * major surgery within 30 days prior to the initiation of study treatment * toxicity from a previous anti-tumor treatment that does not return to grade 0 or 1 (except for alopecia) * patients who are suffering active interstitial lung disease * evidence of ongoing or active serious infection * received corticosteroids treatment or other immunodepressant within 2 weeks before the first dose of study treatment * active hepatitis b or c infection * inability to take medication orally * abuse of alcohol or drugs * pregnant or lactating women * people with cognitive and psychological abnormality or with low compliance
adult study / oros methylphenidate hydrochloride (hcl) (oros mph) in adults with attention deficit hyperactivity disorder (adhd)

Conditions: Attention Deficit Disorder With Hyperactivity

Summary: the purpose of this study is to compare the adhd symptom response of adults with adhd treated with oros mph to those treated with placebo.

the hypothesis is that osmotic release oral system (oros) extended release methylphenidate hcl (oros mph) is safe and effective in improving attention deficit hyperactivity disorder (adhd) symptoms in adults with adhd when compared to placebo as demonstrated using specific study measures. this is a double-blind (neither participant nor investigator knows the name of the assigned study drug), randomized (study drug assigned by chance), placebo-controlled study to evaluate the efficacy and safety of oros mph using the optimal dose for each adult patient in the study with adhd. the primary efficacy variable in this study is the change from baseline to final evaluation using the adult adhd investigator symptom rating scale (aisrs) to measure patient adhd symptoms. participants will also be assessed for adverse events throughout the study. patients will initiate treatment with oral oros mph 18 mg or matching placebo at baseline and continue morning dosing with increases every week until an optimal dose is achieved, up to the maximum of 72 mg/day of oros mph or matching placebo. eligible patients will remain in the study for a maximum of 6 weeks.

Eligibility criteria:
inclusion criteria: * adults * adhd diagnosis (any type: combined, predominantly inattentive, or predominantly hyperactive-impulsive) * patients with an adult adhd investigator symptom rating scale (aisrs) score greater than 24 at screening/baseline * ability to read and understand english exclusion criteria: * any significant history of cardiovascular disease or cardiovascular disease detectable via ecg * history of diagnosis of substance or alcohol dependence or admission/hospitalization for rehabilitation for dependence * current neurologic or psychiatric diagnosis that would make patient inappropriate for participation * anxiety assessments of moderate or severe * depression assessments of moderate or severe * history or current suicidal thoughts or attempts * known allergies, hypersensitivity, or intolerance to oros mph

Keywords: osmotic release oral system (oros®) extended release methylphenidate hcl concerta® (oros mph)
characterization of ovarian masses unable to classify with gynecological ultrasonography: value of pelvic mri with perfusion- and diffusion-weighted imaging

Conditions: Undetermined Ovarian Mass

Summary: the aim of the study is to prospectively evaluate the value of pelvic mri including diffusion- and perfusion-weighted sequences in the selected group of patients that have an undetermined ovarian mass at ultrasound.


Eligibility criteria:
inclusion criteria: \*any woman with an adnexal mass undetermined by gynecological ultrasound exclusion criteria: * any lesion with definite diagnosis by gynecological ultrasound * denial or withdrawal of oral informed consent. * contra-indication for mri

Keywords: pelvic mri
oral ibuprofen versus placebo in treatment of patent ductus arteriosus (pda)in preterm infants

Conditions: Patent Ductus Arteriosus After Premature Birth; Patent Ductus Arteriosus Conservative Management

Summary: the management options of patent ductus arteriosus are still controversial and differ between centers. recently, conservative management has been gaining interest as the evidence of benefit from medical treatment in terms of mortality and morbidity is lacking. this study will compare oral ibuprofen (the standard treatment) with the conservative treatment, in terms of ductal closure and morbidity and mortality at discharge in preterm neonates less than 34 weeks.

a double-blinded, randomized, placebo-control non-inferiority trial was conducted in the neonatal intensive care unit (nicu) of ain shams university children's hospital, cairo, egypt. informed consent was taken from the parents or legal guardians before enrolment, after fully explaining to them the nature of the study. the approval of the research ethics committee at ain shams university was also obtained. all preterm neonates less than 34 weeks were assessed in the first 48 hours by clinical and echocardiographic examination by a cardiologist to detect pda and exclude any congenital heart disease. all neonates meeting the inclusion criteria will be randomized into one of two groups: medical treatment group and placebo group. targeted neonatal echo was repeated after 5 days of the start of medical treatment by a neonatologist or a cardiologist to assess pda closure. after 7 days of intervention, open-label is offered to all patients with the option of another course for patients in the medical treatment group and rescue therapy in the placebo group. the short-term morbidity is documented. withdrawal and replacement of individual subjects: * the attending physician can decide to withdraw a subject from the study for urgent medical reasons. if they wish, parents or caregivers can leave the study at any time for any reason. * infants who are withdrawn from the study will be managed according to nicu protocols.

Eligibility criteria:
inclusion criteria: * gestational age ≤ 34 weeks * pda size \> 1.5 mm and predominantly left-to-right shunt * one of the following: * signs of pulmonary overflow: left atrium/aortic diameter ratio (la/ao), left ventricular end diastolic diameter (lvedd). * signs of systemic hypo perfusion: absent or reversed diastolic flow in the aorta, celiac/mesenteric, or anterior cerebral artery (aca)/ middle cerebral artery (mca) exclusion criteria: * chromosomal anomaly * congenital heart defect, other than pda and/or patent foramen ovale * congenital or acquired gastrointestinal anomaly * previous episodes of necrotizing enterocolitis (nec) or intestinal perforation * active bleeding, especially intracranial or gastrointestinal hemorrhage * contraindications to the use of ibuprofen
internal and familial resources and motherhood. follow up of mothers with twins and preterm infants versus mothers with single full term infants

Conditions: Twins; Preterm Infants

Summary: to evaluate the contribution of internal and familial resources on the development of motherhood in a population of mothers having preterm twin infants and comparing this population to a population of mothers giving birth to single (or twins) full term infants.

150 mothers will participate in this study. the study is using 4 questionnaires at infants ages of 1 month, 1 year, 2 years and 4 years. the questionnaires are involving communication skills,grandparents support, stress feelings, psychological parameters, parity functioning, infant temperament, self assessment, maternal and infant medical background and twins and brotherhood evaluation. a comparison will be done between mothers to preterm twins and mothers to single full term infants.

Eligibility criteria:
inclusion criteria: * preterm infants * twins exclusion criteria: -

Keywords: preterm infants twins motherhood internal resources familial resources
rollover study protocol for pediatric patients in south africa for continued access to emtricitabine

Conditions: HIV-1 Infection

Summary: the primary objectives of this trial are to provide ftc-203 study participants in south africa with continued access to the study drug, emtricitabine (ftc), following completion of the ftc-203 study and to collect long-term safety information in participants receiving emtricitabine in combination with other antiretroviral agents.


Eligibility criteria:
key inclusion criteria: * complete or have previously completed at least through the week 96 visit (i.e., 96 weeks on study) for the ftc-203 study. * complete all end-of-study visit procedures for the ftc-203 study. * either (a) have a plasma hiv-1 rna viral load of ≤ 400 copies/ml at the end-of-study visit for the ftc-203 study, or (b) if the subject's plasma hiv-1 rna viral load at the end-of-study visit for ftc-203 study is \> 400 copies/ml, their viral load is \< 1.0 log10 above the nadir recorded after week 8 of the ftc-203 study and there is reliable genotypic evidence showing a lack of resistance to emtricitabine. * a parent or other legal guardian has provided written informed consent to the subject participating in the rollover protocol. as applicable, based on the subject's age and normal institution practice, the subject should additionally provide their written informed consent or assent to participate in the rollover protocol. note: other protocol defined inclusion/exclusion criteria may apply.

Keywords: hiv-1 infection emtricitabine pediatrics pediatric patients
research of the application of triple antibiotic paste in primary teeth with pericpical periodontitis

Conditions: Periapical Diseases

Summary: the triple antibiotic paste is widely used in young permanent teeth and permanent teeth root canal therapy with excellent antiantimicrobial effect.we hypothesize that its application in the treatment of periapical periodontitis of deciduous teeth is superior to other drugs currently in use as creosote.

we design to collect a group of patients presenting primary teeth with periapical periodontitis in certain criterion. we will divide the patients into two groups randomly.one group will get treated with triple antibiotic paste while the other with creosote.we want to evaluate the short-term and long-term effects of the two groups to get a conclusion of the clinical value of triple antibiotic paste.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of periapical periodontitis * must be primary teeth * must be 3\~8 years old * the permanent tooth germ is complete and didnot be involved exclusion criteria: * blood disease * residual root that is advised to extract * serious periodontitis * allergy to the triple antibiotic paste

Keywords: periapical periodontitis,primary teeth
adipose derived stem cells versus platelet rich plasma on follicular unit extraction

Conditions: Androgenetic Alopecia

Summary: androgenetic alopecia is the most common type of alopecia in both men and women. about 80 % of caucasian men and 40-50 % of caucasian women are affected by androgenetic alopecia. the psychological impact of hair loss due to androgenetic alopecia can be profound.

currently, two medications are food and drug administration approved in the treatment of androgenetic alopecia which are minoxidil, and finasteride. both medications must be taken indefinitely for benefits to persist. hair transplantation is the only current successful permanent option. nowadays, the majority of surgeons use 2 techniques, the classic strip technique, and the follicular unit extraction technique. advantages of follicular unit extraction over the strip technique are the lesser incidence of donor zone post-procedural discomfort and the barely visible scarring. platelet rich plasma is an autologous concentration of platelets in small volume of plasma and is an exciting therapeutic option for hair growth. combining platelet rich plasma with follicular unit extraction surgery for the treatment of androgenetic alopecia demonstrated that prp is able to minimize the postsurgical follicle loss and potentiate the performance of grafted hairs. adipose derived stem cells are an effective mesenchymal stem cell population with enormous potential in different fields of regenerative medicine. adipose stem cells are needed to induce the proliferation of bulge stem cells of hair follicle. furthermore, they can help in wound healing and vascular neogenesis. zanzottera et al. 2014 investigated the effect of adipose derived stem cells on wound healing and engraftment of the transplanted hair applied during hair restoration surgery for three patients with androgenetic alopecia. despite their promising results, further clinical trials including larger number of patients are still needed to confirm their preliminary findings.

Eligibility criteria:
inclusion criteria: * male patients with androgenetic alopecia between 18 years and 60 years exclusion criteria: 1. patients with non-androgenetic causes of hair loss. 2. female patients with androgenetic alopecia. 3. patients who received anti-hair loss treatment within the past six months. 4. patients with history of bleeding disorders or on anticoagulant therapy. 5. patients with history of chronic liver disease, cancer or connective tissue disorders. 6. patients with current scalp infection.

Keywords: platelet rich plasma adipose derived stem cells follicular unit extraction hair transplantation
cerebral oximetry and nirs in cardiac arrest patients

Conditions: Cardiac Death; Cardiac Arrest; Emergencies

Summary: this is an observational study to define the role and future applications of cerebral oximetry in cardiac arrest patients.


Eligibility criteria:
inclusion criteria: * age \> 18 years * non-traumatic cardiac arrest or post non-traumatic cardiac arrest * no purposeful response to verbal or noxious stimuli exclusion criteria: * age \< 18 years * open head injury/trauma

Keywords: cardiac arrest, cardiac death, cpr, neurologic prognostication, emergency medicine,
wear (wearability and evaluation of adjustable refraction) iii

Conditions: Myopia

Summary: two-month randomized trial comparing three groups.

two-month randomized non-inferiority trial (the margin of non-inferiority is 20%) comparing three groups: self-refraction with adjustable glasses, receiving adjustable glasses; subjective refraction by an expert refractionist after computer optometry and receiving custom standard glasses; subjective refraction by an expert refractionist after computer optometry and receiving ready-made glasses. the main outcome of this study is the rate of glasses wear on twice-weekly covert evaluation by head teachers. and the continuous teacher assessment of wearing study glasses will be calculated as the number of times wearing glasses/ total number of separate observations.

Eligibility criteria:
inclusion criteria: * 11-16 years old middle school students from two locations in guangdong province. * with ≤ -1.00 diopter of myopic refractive error in each eye. * with uncorrected vision ≤ 6/12 in both eyes thought to be due to refractive error (that is, correctable to at least 6/7.5 with subjective refraction by an optometrist). * with informed consents(there are two types of informed consents. one of them is whether the parents of the students agree their kids to participate in the project. the other informed consent is whether the parents agree their kids to have the cycloplegic refraction. if the students were admitted to participate in project but without being agreed to have cycloplegic refraction by their parents , they would have non cycloplegic retinoscopy.). exclusion criteria: * those corrected va can not up to 6/7.5 with subjective refraction by an optometrist. * those with significant strabismus or vision abnormality (keratopathy, cataract, vitreous macular diseases ), or with vision deficiency ( amblyopia ) children are to be excluded. * children developing acquired vision problems other than myopia.

Keywords: myopia self-refraction glasses spectacles